+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2019

  • ID: 4760842
  • Drug Pipelines
  • 150 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Aptinyx Inc
  • Can-Fite BioPharma Ltd
  • Insys Therapeutics Inc
  • MAKScientific LLC
  • Nemus Bioscience Inc
  • MORE
Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2019, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

Report Highlights

This latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3, 20 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from 's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Aptinyx Inc
  • Can-Fite BioPharma Ltd
  • Insys Therapeutics Inc
  • MAKScientific LLC
  • Nemus Bioscience Inc
  • MORE
Introduction

Chemotherapy Induced Peripheral Neuropathy - Overview

Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development

Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment

Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development

Chemotherapy Induced Peripheral Neuropathy - Drug Profiles

Chemotherapy Induced Peripheral Neuropathy - Dormant Projects

Chemotherapy Induced Peripheral Neuropathy - Discontinued Products

Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aphios Corp, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Pharma Corp, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Can-Fite BioPharma Ltd, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Celgene Corp, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Insys Therapeutics Inc, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta Inc, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific LLC, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Metys Pharmaceuticals AG, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mundipharma International Ltd, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience Inc, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen Inc, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sensei Biotherapeutics Inc, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals Inc, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Stealth BioTherapeutics Corp, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Trevena Inc, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2019 (Contd..1), H1 2019

Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Achelios Therapeutics Inc
  • Aphios Corp
  • Aptinyx Inc
  • Asahi Kasei Pharma Corp
  • Can-Fite BioPharma Ltd
  • Celgene Corp
  • Immune Pharmaceuticals Inc
  • Insys Therapeutics Inc
  • Kineta Inc
  • Kyorin Pharmaceutical Co Ltd
  • MAKScientific LLC
  • Metys Pharmaceuticals AG
  • Mundipharma International Ltd
  • Nemus Bioscience Inc
  • PeriphaGen Inc
  • PledPharma AB
  • Sensei Biotherapeutics Inc
  • Sova Pharmaceuticals Inc
  • Stealth BioTherapeutics Corp
  • Trevena Inc
  • WEX Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4760842
Adroll
adroll